Haemato AG Stock
Price
Target price
€15.05
€15.05
0.330%
0.05
0.330%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Haemato AG Stock
The Haemato AG stock is trending slightly upwards today, with an increase of €0.050 (0.330%) compared to yesterday's price.
So far the community has only identified positive things for Haemato AG stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Haemato AG in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Haemato AG vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Haemato AG | 0.330% | 0.333% | -11.988% | -14.972% | -44.259% | -46.250% | - |
MPH Health Care AG | 3.880% | -0.962% | -8.444% | 38.255% | 24.096% | -28.472% | -52.204% |
Biotest AG ST | -0.480% | -1.429% | -2.358% | -2.358% | -2.358% | 43.253% | 68.980% |
Biotest AG VZ | 1.040% | 0.694% | 9.848% | -9.375% | -6.452% | -0.685% | 29.464% |
News
EQS-Adhoc: HAEMATO AG: Termination of listing in the Open Market
EQS-Adhoc: HAEMATO AG: Termination of listing in the Open Market
EQS-News: HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in
EQS-News: HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in
EQS-Adhoc: Termination of the botulinum toxin project
EQS-Adhoc: Termination of the botulinum toxin project